TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Next-Generation Breast Cancer Diagnostic and Screening Market Insights, Forecast to 2028

Global Next-Generation Breast Cancer Diagnostic and Screening Market Insights, Forecast to 2028

  • Category:Life Sciences
  • Published on : 26 August 2022
  • Pages :110
  • Formats:
  • Report Code:SMR-7294860
OfferClick for best price

Best Price: $3920

NextGeneration Breast Cancer Diagnostic Screening Market Size, Share 2022


Market Analysis and Insights: Global NextGeneration Breast Cancer Diagnostic Screening Market

The global NextGeneration Breast Cancer Diagnostic Screening market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global NextGeneration Breast Cancer Diagnostic Screening market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global NextGeneration Breast Cancer Diagnostic Screening market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global NextGeneration Breast Cancer Diagnostic Screening market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global NextGeneration Breast Cancer Diagnostic Screening market.

Global NextGeneration Breast Cancer Diagnostic Screening Scope and Market Size

Next-Generation Breast Cancer Diagnostic and Screening market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Next-Generation Breast Cancer Diagnostic and Screening market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

Real-Time PCR (q-PCR)

Immunohistochemistry (IHC)

Next-Generation Sequencing (NGS)

Fluorescent In-Situ Hybridization (FISH)

Segment by Application

Hospital-associated Labs

Cancer Research Institutes

Diagnostic Centers

By Company

Abbott Laboratories

Agendia

Agilent Technologies

Ambry Genetics

Biocept

Biotheranostics

Centogene

Danaher Corporation

EXACT Sciences Corporation

Roche Holding AG

Fulgent Genetics

Illumina

Invitae

Lucence Diagnostics Pte Ltd

Myriad Genetics

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes NextGeneration Breast Cancer Diagnostic Screening product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of NextGeneration Breast Cancer Diagnostic Screening, with price, sales, revenue, and global market share of NextGeneration Breast Cancer Diagnostic Screening from 2019 to 2022.

Chapter 3, the NextGeneration Breast Cancer Diagnostic Screening competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the NextGeneration Breast Cancer Diagnostic Screening breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the NextGeneration Breast Cancer Diagnostic Screening market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of NextGeneration Breast Cancer Diagnostic Screening.

Chapter 13, 14, and 15, to describe NextGeneration Breast Cancer Diagnostic Screening sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 NextGeneration Breast Cancer Diagnostic Screening Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global Next-Generation Breast Cancer Diagnostic and Screening Market Insights, Forecast to 2028
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 110 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Real-Time PCR (q-PCR)
1.2.3 Immunohistochemistry (IHC)
1.2.4 Next-Generation Sequencing (NGS)
1.2.5 Fluorescent In-Situ Hybridization (FISH)
1.3 Market by Application
1.3.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital-associated Labs
1.3.3 Cancer Research Institutes
1.3.4 Diagnostic Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Perspective (2017-2028)
2.2 Next-Generation Breast Cancer Diagnostic and Screening Growth Trends by Region
2.2.1 Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Region (2017-2022)
2.2.3 Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Region (2023-2028)
2.3 Next-Generation Breast Cancer Diagnostic and Screening Market Dynamics
2.3.1 Next-Generation Breast Cancer Diagnostic and Screening Industry Trends
2.3.2 Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
2.3.3 Next-Generation Breast Cancer Diagnostic and Screening Market Challenges
2.3.4 Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue
3.1.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue (2017-2022)
3.1.2 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Players (2017-2022)
3.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Next-Generation Breast Cancer Diagnostic and Screening Revenue
3.4 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio
3.4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2021
3.5 Next-Generation Breast Cancer Diagnostic and Screening Key Players Head office and Area Served
3.6 Key Players Next-Generation Breast Cancer Diagnostic and Screening Product Solution and Service
3.7 Date of Enter into Next-Generation Breast Cancer Diagnostic and Screening Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Type
4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Type (2017-2022)
4.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2023-2028)
5 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Application
5.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Application (2017-2022)
5.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2017-2028)
6.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type
6.2.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022)
6.2.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2023-2028)
6.2.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type (2017-2028)
6.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application
6.3.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022)
6.3.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2023-2028)
6.3.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application (2017-2028)
6.4 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
6.4.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2017-2022)
6.4.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size (2017-2028)
7.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type
7.2.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022)
7.2.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2023-2028)
7.2.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type (2017-2028)
7.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application
7.3.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022)
7.3.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2023-2028)
7.3.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application (2017-2028)
7.4 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
7.4.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2017-2022)
7.4.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size (2017-2028)
8.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type
8.2.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type (2017-2028)
8.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application
8.3.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application (2017-2028)
8.4 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region
8.4.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2017-2028)
9.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type
9.2.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022)
9.2.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2023-2028)
9.2.3 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type (2017-2028)
9.3 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application
9.3.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022)
9.3.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2023-2028)
9.3.3 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application (2017-2028)
9.4 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
9.4.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2017-2022)
9.4.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size (2017-2028)
10.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type
10.2.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type (2017-2028)
10.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application
10.3.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application (2017-2028)
10.4 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
10.4.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.1.4 Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.1.5 Abbott Laboratories Recent Developments
11.2 Agendia
11.2.1 Agendia Company Details
11.2.2 Agendia Business Overview
11.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.2.4 Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.2.5 Agendia Recent Developments
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Details
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.3.4 Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.3.5 Agilent Technologies Recent Developments
11.4 Ambry Genetics
11.4.1 Ambry Genetics Company Details
11.4.2 Ambry Genetics Business Overview
11.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.4.4 Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.4.5 Ambry Genetics Recent Developments
11.5 Biocept
11.5.1 Biocept Company Details
11.5.2 Biocept Business Overview
11.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.5.4 Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.5.5 Biocept Recent Developments
11.6 Biotheranostics
11.6.1 Biotheranostics Company Details
11.6.2 Biotheranostics Business Overview
11.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.6.4 Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.6.5 Biotheranostics Recent Developments
11.7 Centogene
11.7.1 Centogene Company Details
11.7.2 Centogene Business Overview
11.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.7.4 Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.7.5 Centogene Recent Developments
11.8 Danaher Corporation
11.8.1 Danaher Corporation Company Details
11.8.2 Danaher Corporation Business Overview
11.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.8.4 Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.8.5 Danaher Corporation Recent Developments
11.9 EXACT Sciences Corporation
11.9.1 EXACT Sciences Corporation Company Details
11.9.2 EXACT Sciences Corporation Business Overview
11.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.9.4 EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.9.5 EXACT Sciences Corporation Recent Developments
11.10 Roche Holding AG
11.10.1 Roche Holding AG Company Details
11.10.2 Roche Holding AG Business Overview
11.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.10.4 Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.10.5 Roche Holding AG Recent Developments
11.11 Fulgent Genetics
11.11.1 Fulgent Genetics Company Details
11.11.2 Fulgent Genetics Business Overview
11.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.11.4 Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.11.5 Fulgent Genetics Recent Developments
11.12 Illumina
11.12.1 Illumina Company Details
11.12.2 Illumina Business Overview
11.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.12.4 Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.12.5 Illumina Recent Developments
11.13 Invitae
11.13.1 Invitae Company Details
11.13.2 Invitae Business Overview
11.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.13.4 Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.13.5 Invitae Recent Developments
11.14 Lucence Diagnostics Pte Ltd
11.14.1 Lucence Diagnostics Pte Ltd Company Details
11.14.2 Lucence Diagnostics Pte Ltd Business Overview
11.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.14.4 Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.14.5 Lucence Diagnostics Pte Ltd Recent Developments
11.15 Myriad Genetics
11.15.1 Myriad Genetics Company Details
11.15.2 Myriad Genetics Business Overview
11.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.15.4 Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.15.5 Myriad Genetics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Real-Time PCR (q-PCR)
Table 3. Key Players of Immunohistochemistry (IHC)
Table 4. Key Players of Next-Generation Sequencing (NGS)
Table 5. Key Players of Fluorescent In-Situ Hybridization (FISH)
Table 6. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 7. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2017-2022) & (US$ Million)
Table 9. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2017-2022)
Table 10. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 11. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2023-2028)
Table 12. Next-Generation Breast Cancer Diagnostic and Screening Market Trends
Table 13. Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
Table 14. Next-Generation Breast Cancer Diagnostic and Screening Market Challenges
Table 15. Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
Table 16. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Players (2017-2022) & (US$ Million)
Table 17. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Players (2017-2022)
Table 18. Global Top Next-Generation Breast Cancer Diagnostic and Screening by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2021)
Table 19. Ranking of Global Top Next-Generation Breast Cancer Diagnostic and Screening Companies by Revenue (US$ Million) in 2021
Table 20. Global 5 Largest Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue (CR5 and HHI) & (2017-2022)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Next-Generation Breast Cancer Diagnostic and Screening Product Solution and Service
Table 23. Date of Enter into Next-Generation Breast Cancer Diagnostic and Screening Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022) & (US$ Million)
Table 26. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2017-2022)
Table 27. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 28. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2023-2028)
Table 29. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022) & (US$ Million)
Table 30. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Application (2017-2022)
Table 31. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 32. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Application (2023-2028)
Table 33. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022) & (US$ Million)
Table 34. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2023-2028) & (US$ Million)
Table 35. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022) & (US$ Million)
Table 36. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2023-2028) & (US$ Million)
Table 37. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2017-2022) & (US$ Million)
Table 38. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2023-2028) & (US$ Million)
Table 39. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022) & (US$ Million)
Table 40. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2023-2028) & (US$ Million)
Table 41. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022) & (US$ Million)
Table 42. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2023-2028) & (US$ Million)
Table 43. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2017-2022) & (US$ Million)
Table 44. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2023-2028) & (US$ Million)
Table 45. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022) & (US$ Million)
Table 46. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2023-2028) & (US$ Million)
Table 47. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022) & (US$ Million)
Table 48. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2023-2028) & (US$ Million)
Table 49. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2017-2022) & (US$ Million)
Table 50. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2023-2028) & (US$ Million)
Table 51. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022) & (US$ Million)
Table 52. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2023-2028) & (US$ Million)
Table 53. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022) & (US$ Million)
Table 54. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2023-2028) & (US$ Million)
Table 55. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2017-2022) & (US$ Million)
Table 56. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2023-2028) & (US$ Million)
Table 61. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2017-2022) & (US$ Million)
Table 62. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2023-2028) & (US$ Million)
Table 63. Abbott Laboratories Company Details
Table 64. Abbott Laboratories Business Overview
Table 65. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product
Table 66. Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022) & (US$ Million)
Table 67. Abbott Laboratories Recent Developments
Table 68. Agendia Company Details
Table 69. Agendia Business Overview
Table 70. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product
Table 71. Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022) & (US$ Million)
Table 72. Agendia Recent Developments
Table 73. Agilent Technologies Company Details
Table 74. Agilent Technologies Business Overview
Table 75. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product
Table 76. Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022) & (US$ Million)
Table 77. Agilent Technologies Recent Developments
Table 78. Ambry Genetics Company Details
Table 79. Ambry Genetics Business Overview
Table 80. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 81. Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022) & (US$ Million)
Table 82. Ambry Genetics Recent Developments
Table 83. Biocept Company Details
Table 84. Biocept Business Overview
Table 85. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product
Table 86. Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022) & (US$ Million)
Table 87. Biocept Recent Developments
Table 88. Biotheranostics Company Details
Table 89. Biotheranostics Business Overview
Table 90. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 91. Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022) & (US$ Million)
Table 92. Biotheranostics Recent Developments
Table 93. Centogene Company Details
Table 94. Centogene Business Overview
Table 95. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product
Table 96. Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022) & (US$ Million)
Table 97. Centogene Recent Developments
Table 98. Danaher Corporation Company Details
Table 99. Danaher Corporation Business Overview
Table 100. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product
Table 101. Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022) & (US$ Million)
Table 102. Danaher Corporation Recent Developments
Table 103. EXACT Sciences Corporation Company Details
Table 104. EXACT Sciences Corporation Business Overview
Table 105. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product
Table 106. EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022) & (US$ Million)
Table 107. EXACT Sciences Corporation Recent Developments
Table 108. Roche Holding AG Company Details
Table 109. Roche Holding AG Business Overview
Table 110. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product
Table 111. Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022) & (US$ Million)
Table 112. Roche Holding AG Recent Developments
Table 113. Fulgent Genetics Company Details
Table 114. Fulgent Genetics Business Overview
Table 115. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 116. Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022) & (US$ Million)
Table 117. Fulgent Genetics Recent Developments
Table 118. Illumina Company Details
Table 119. Illumina Business Overview
Table 120. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product
Table 121. Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022) & (US$ Million)
Table 122. Illumina Recent Developments
Table 123. Invitae Company Details
Table 124. Invitae Business Overview
Table 125. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product
Table 126. Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022) & (US$ Million)
Table 127. Invitae Recent Developments
Table 128. Lucence Diagnostics Pte Ltd Company Details
Table 129. Lucence Diagnostics Pte Ltd Business Overview
Table 130. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product
Table 131. Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022) & (US$ Million)
Table 132. Lucence Diagnostics Pte Ltd Recent Developments
Table 133. Myriad Genetics Company Details
Table 134. Myriad Genetics Business Overview
Table 135. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 136. Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022) & (US$ Million)
Table 137. Myriad Genetics Recent Developments
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type: 2021 VS 2028
Figure 2. Real-Time PCR (q-PCR) Features
Figure 3. Immunohistochemistry (IHC) Features
Figure 4. Next-Generation Sequencing (NGS) Features
Figure 5. Fluorescent In-Situ Hybridization (FISH) Features
Figure 6. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application: 2021 VS 2028
Figure 7. Hospital-associated Labs Case Studies
Figure 8. Cancer Research Institutes Case Studies
Figure 9. Diagnostic Centers Case Studies
Figure 10. Next-Generation Breast Cancer Diagnostic and Screening Report Years Considered
Figure 11. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 12. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region: 2021 VS 2028
Figure 14. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Players in 2021
Figure 15. Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2021)
Figure 16. The Top 10 and 5 Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2021
Figure 17. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY (2017-2028) & (US$ Million)
Figure 18. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size Market Share by Type (2017-2028)
Figure 19. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size Market Share by Application (2017-2028)
Figure 20. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size Share by Country (2017-2028)
Figure 21. United States Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY (2017-2028) & (US$ Million)
Figure 24. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size Market Share by Type (2017-2028)
Figure 25. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size Market Share by Application (2017-2028)
Figure 26. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size Share by Country (2017-2028)
Figure 27. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. France Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. U.K. Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Russia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Nordic Countries Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY (2017-2028) & (US$ Million)
Figure 34. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size Market Share by Type (2017-2028)
Figure 35. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size Market Share by Application (2017-2028)
Figure 36. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size Share by Region (2017-2028)
Figure 37. China Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. India Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 43. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY (2017-2028) & (US$ Million)
Figure 44. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size Market Share by Type (2017-2028)
Figure 45. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size Market Share by Application (2017-2028)
Figure 46. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size Share by Country (2017-2028)
Figure 47. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY (2017-2028) & (US$ Million)
Figure 50. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size Market Share by Type (2017-2028)
Figure 51. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size Market Share by Application (2017-2028)
Figure 52. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size Share by Country (2017-2028)
Figure 53. Turkey Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. UAE Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. Abbott Laboratories Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
Figure 57. Agendia Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
Figure 58. Agilent Technologies Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
Figure 59. Ambry Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
Figure 60. Biocept Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
Figure 61. Biotheranostics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
Figure 62. Centogene Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
Figure 63. Danaher Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
Figure 64. EXACT Sciences Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
Figure 65. Roche Holding AG Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
Figure 66. Fulgent Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
Figure 67. Illumina Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
Figure 68. Invitae Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
Figure 69. Lucence Diagnostics Pte Ltd Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
Figure 70. Myriad Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount